Investigational New Drug

What an Investigational New Drug Means in Everyday Medical Language

An Investigational New Drug (IND) is a medicine that has been tested in laboratories and animals and has received approval from the U.S. Food and Drug Administration (FDA) to be tested in people. These drugs are also called experimental or investigational drugs because they are still being studied to learn if they are safe and effective. While some INDs may be approved by the FDA for one disease or condition, they can still be considered investigational for other diseases or uses.

Why Investigational New Drugs Matter in Cancer Care

INDs represent new treatment options that are not yet widely available. They may offer hope for patients whose cancer has not responded to standard treatments. Researchers study these drugs in clinical trials to find out how well they work and whether they are safe. This research helps improve cancer care by discovering better therapies. However, because INDs are still being tested, their benefits and risks are not fully known.

Where Patients Might See or Hear the Term IND

The term IND may appear in medical records, treatment plans, clinical trial information, or drug information pages. It might come up when your healthcare team discusses new or experimental treatments being considered or offered. You might also see related terms like experimental drug, investigational agent, or investigational drug. Because these terms all refer to the same concept, comparing the wording in your reports or sources can help avoid confusion.

What IND Does Not Automatically Mean

Seeing the term IND does not mean you have been diagnosed with a new disease or that you must take an experimental drug. It simply means a drug is being studied and may be available through research or special programs. IND is not a treatment recommendation by itself. Also, being offered an IND does not guarantee it will work or be free of side effects. These drugs have not yet completed the full approval process, so their safety and effectiveness are still being studied.

How Patients Can Access Investigational New Drugs

The most common way to access an IND is by joining a clinical trial, which is a research study designed to learn if the drug is safe and effective. Sometimes, patients with serious illnesses who cannot join trials may get access through special programs like expanded access (also called compassionate use) or right to try. These programs have specific rules and require approval from doctors, drug companies, and sometimes the FDA. Your healthcare provider can help you understand if these options might be appropriate for you.

Common Questions to Ask Your Care Team

If you hear about an investigational new drug, you might ask your care team: What does this drug or treatment mean for my care? Is this drug part of a clinical trial or another program? What are the potential benefits and risks? How does this option compare to standard treatments? Understanding these points can help you make informed decisions about your care.

Understanding the Term in Context and Next Steps

Because the term IND can be confusing, it’s important to ask your care team exactly how it applies to your situation rather than assuming it means a diagnosis or a recommended treatment. This glossary entry is educational and does not decide what is safe, appropriate, or effective for any individual patient. If the term appears in your medical records or discussions, the safest next step is to ask your healthcare provider what it means for your specific care and treatment options.